EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor ( MOR ) ligands in female and male mice. II . Effects of novel MOR ‐selective phenylmorphans with high‐to‐low MOR efficacy

Edna J Santos, Nima Nassehi, Eric W Bow, Dana R Chambers, Eugene S Gutman, Arthur E Jacobson, Joshua A Lutz, Samuel A Marsh, Kenner C Rice, Agnieszka Sulima, Dana E Selley, S Stevens Negus iD

Pharmacology Research & Perspectives · 2023

DOI: 10.1002/prp2.1111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Edna J Santos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Buprenorphine, Receptors, Opioid, mu. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIDA NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low‐efficacy mu‐opioid receptor (MOR) agonists represent promising therapeutics, but existing compounds (e.g., buprenorphine, nalbuphine) span a limited range of low MOR efficacies and have poor MOR selectivity. Accordingly, new and selective low‐efficacy MOR agonists are of interest. A novel set of chiral C9‐substituted phenylmorphans has been reported to display improved MOR selectivity and a range of high‐to‐low MOR efficacies under other conditions; however, a full opioid receptor binding profile for these drugs has not been described. Additionally, studies in mice will be useful for preclinical characterization of these novel compounds, but the pharmacology of these drugs in mice has also not been examined. Accordingly, the present study characterized the binding selectivity and in vitro efficacy of these compounds using assays of opioid receptor binding and ligand‐stimulated [ 35 S]GTPɣS binding. Additionally, locomotor effects were evaluated as a first step for in vivo behavioral assessment in mice. The high‐efficacy MOR agonist and clinically effective antidepressant tianeptine was included as a comparator. In binding studies, all phenylmorphans showed improved MOR selectivity relative to existing lower‐efficacy MOR agonists. In the ligand‐stimulated [ 35 S]GTPɣS binding assay, seven phenylmorphans had graded levels of sub‐buprenorphine MOR efficacy. In locomotor studies, the compounds again showed graded efficacy with a rapid onset and ≥1 h duration of effects, evidence for MOR mediation, and minor sex differences. Tianeptine functioned as a high‐efficacy MOR agonist. Overall, these in vitro and in vivo studies support the characterization of these compounds as MOR‐selective ligands with graded MOR efficacy and utility for further behavioral studies in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidBuprenorphineReceptors, Opioid, muAnimalsFemaleMaleMiceGuanosine 5'-O-(3-Thiotriphosphate)LigandsMorphinansThiazepines

Stichwörter der Autor:innen

efficacylocomotor activitymousemu opioid receptoropioidreceptor binding

Substanzen

Analgesics, OpioidBuprenorphineGuanosine 5'-O-(3-Thiotriphosphate)LigandsReceptors, Opioid, muphenylmorphanMorphinanstianeptineThiazepines

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland, USA.

ORCID-Profile: S Stevens Negus

Förderung

  • NINDS NIH HHS
  • NIDA NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Drug Abuse

Zitieren

APA

Santos, E. J., Nassehi, N., Bow, E. W., Chambers, D. R., Gutman, E. S., Jacobson, A. E., Lutz, J. A., Marsh, S. A., Rice, K. C., Sulima, A., Selley, D. E., & Negus, S. S. (2023). Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor ( MOR ) ligands in female and male mice. II . Effects of novel MOR ‐selective phenylmorphans with high‐to‐low MOR efficacy. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1111

Vancouver

Santos EJ, Nassehi N, Bow EW, Chambers DR, Gutman ES, Jacobson AE, et al. Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor ( MOR ) ligands in female and male mice. II . Effects of novel MOR ‐selective phenylmorphans with high‐to‐low MOR efficacy. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1111

BibTeX
@article{Santos2023,
  author = {Santos, Edna J and Nassehi, Nima and Bow, Eric W and Chambers, Dana R and Gutman, Eugene S and Jacobson, Arthur E and Lutz, Joshua A and Marsh, Samuel A and Rice, Kenner C and Sulima, Agnieszka and Selley, Dana E and Negus, S Stevens},
  title = {Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor ( MOR ) ligands in female and male mice. II . Effects of novel MOR ‐selective phenylmorphans with high‐to‐low MOR efficacy},
  journal = {Pharmacology Research & Perspectives},
  year = {2023},
  doi = {10.1002/prp2.1111}
}
Kostenlos starten →